VVOS · Vivos Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Skaff Michael C | ▲ Buy | Open Market | 1,353,625 Shares held | 3/31/2026 | View profile |
| Amman Bradford K. Principal Accounting Officer | ▲ Buy | Grant | 250,080 Shares held | 7/31/2026 | View profile |
| Huntsman Ronald Kirk Chief Executive Officer | ▼ Sell | Other | 85,910 Shares held | 6/30/2026 | View profile |
Transaction History
| Amman Bradford K. | ▲ Buy | Grant | 250,000 | $103K | 7/31/2026 |
| Huntsman Ronald Kirk | ▼ Sell | Other | 85,910 | $50K | 6/30/2026 |
| Skaff Michael C | ▲ Buy | Open Market | 1,044,777 | $1.4M | 3/31/2026 |
| Skaff Michael C | ▲ Buy | Open Market | 308,848 | $414K | 3/31/2026 |
| Huntsman Ronald Kirk | ▲ Buy | Open Market | 14,000 | $7K | 6/20/2023 |
| Huntsman Ronald Kirk | ▲ Buy | Open Market | 10,000 | $5K | 6/16/2023 |
| Huntsman Ronald Kirk | ▲ Buy | Open Market | 5,000 | $3K | 6/16/2023 |
| Huntsman Ronald Kirk | ▲ Buy | Open Market | 21 | $11 | 6/15/2023 |
| Huntsman Ronald Kirk | ▲ Buy | Open Market | 10,000 | $5K | 6/14/2023 |
| Huntsman Ronald Kirk | ▲ Buy | Open Market | 20,000 | $10K | 12/23/2022 |
| Huntsman Ronald Kirk | ▲ Buy | Open Market | 4,000 | $7K | 6/1/2022 |
| Huntsman Ronald Kirk | ▲ Buy | Open Market | 8,000 | $16K | 5/31/2022 |
| Huntsman Ronald Kirk | ▲ Buy | Open Market | 5,000 | $22K | 9/21/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
VVOS Announces $3.6M Annual Cost‑Reduction Plan
Vivos Therapeutics disclosed a restructuring plan that aims to cut annual costs by $3.6 million beginning in the fourth quarter of 2026. The company also reported progress on material cost reductions and initiatives to grow revenue. These actions are intended to improve financial efficiency while supporting ongoing growth efforts.
VVOS Announces $3.6M Annual Cost‑Reduction Plan. Vivos Therapeutics disclosed a restructuring plan that aims to cut annual costs by $3.6 million beginning in the fourth quarter of 2026. The company also reported progress on material cost reductions and initiatives to grow revenue. These actions are intended to improve financial efficiency while supporting ongoing growth efforts.